New Macular Degeneration Treatment Now Available! Learn More

phone-icon 888-NY-LASIK Book Appointment

Wet Age-Related Macular Degeneration

A Treatment Plan Built Around Your Vision

Wet AMD is a treatable, time-sensitive form of macular disease caused by abnormal blood vessel growth under the retina, not an inevitable loss of central vision.

Anti-VEGF injections are the established first-line therapy, and newer agents now allow many patients to maintain vision with as few as one injection every three to four months.

Sudden distortion of straight lines, a new central blind spot, or rapid blur deserves a same-week retinal evaluation, not a routine appointment in six months.

At NY LASIK in New York City, treatment decisions are anchored in published clinical evidence, optical coherence tomography findings, and how your disease responds, not a one-size protocol.

Wet AMD Is Not Defined by the Injection. It Is Defined by What the Injection Protects.

Your macula is a few millimeters of tissue at the center of the retina, and it carries almost everything that defines functional vision: reading, faces, color, the road ahead. In wet age-related macular degeneration, abnormal blood vessels grow under that tissue and leak fluid or blood, which lifts and damages the photoreceptors with surgical precision but no surgical benefit. Left untreated, the result is a permanent central blind spot, even when peripheral vision is preserved.

For nearly two decades, the standard of care has been intravitreal anti-VEGF therapy, monthly injections of medication that blocks the vascular endothelial growth factor (VEGF) signal driving that neovascularization. The science is well established. In landmark trials, roughly 95 percent of patients receiving monthly anti-VEGF avoided clinically significant vision loss at one year, compared with 62 percent on placebo treatment. The injections work.

But monthly injections for a decade or more are no longer the only path. New-generation anti-VEGF agents and treat-and-extend protocols now allow most patients to maintain those visual gains with substantially fewer visits. At NY LASIK, serving patients across Manhattan, Brooklyn, Queens, and the greater New York metropolitan area, we do not offer the old monthly cadence when the evidence supports a more durable, less burdensome plan. The goal is the same. The path is no longer the same.

Not a marketing distinction. A clinical one, grounded in two-year, peer-reviewed outcomes.

Book Appointment
Home Wet Age-Related Macular Degeneration
healthy senior woman walking in the city

Understanding Wet AMD: What Happens Inside the Eye

AMD is a degenerative disease of the macula that affects an enormous portion of the aging population. The CDC’s Vision and Eye Health Surveillance System estimates that about 19.83 million Americans aged 40 and older have some form of AMD, and 1.49 million have the vision-threatening late stage. Wet AMD, also called neovascular or exudative AMD, accounts for a smaller fraction of cases but is responsible for the majority of severe AMD-related vision loss.

The disease usually begins in its dry form, with the accumulation of yellowish lipoprotein deposits called drusen under the retina. In some patients, that environment triggers the growth of fragile new blood vessels from the choroid into and under the retina, a process known as choroidal neovascularization. These vessels leak fluid and blood, distorting the architecture of the macula and leading to photoreceptor loss and central vision loss if not treated promptly.

The biological trigger for those abnormal vessels is vascular endothelial growth factor, or VEGF. Every modern wet AMD therapy is built around interrupting that signal.

Happy senior couple spending time at the beach in New York

Symptoms That Require a Same-Week Evaluation

Wet AMD does not announce itself with pain. The earliest warning signs are visual and often subtle:

  • Sudden distortion of straight lines, such as door frames or text appearing wavy
  • A new dark or blurry spot in your central vision
  • Rapid worsening of central blur in one eye
  • Difficulty recognizing faces or reading despite a current eyeglass prescription
  • Colors appearing washed out

The earlier active wet AMD is treated, the more visual function we can preserve. Patients with established dry AMD should monitor their central vision daily with an Amsler grid and contact a retina specialist within days, not weeks, if any of these symptoms appear. The clinical principle is consistent across the American Academy of Ophthalmology’s Preferred Practice Pattern guidelines: time-to-treatment matters.

healthy mature woman close up eyes

How Wet AMD Is Diagnosed

Diagnosis begins with a dilated retinal examination, but confirming wet AMD requires imaging. At NY LASIK we use a layered approach:

  • Optical coherence tomography (OCT): A non-contact infrared scan that produces cross-sectional images of the retina, allowing us to see intraretinal and subretinal fluid, retinal thickening, and pigment epithelial detachments that signal active neovascularization.
  • OCT angiography (OCTA): A dye-free imaging method that maps the abnormal vessels directly.
  • Fluorescein angiography: An intravenous dye study used when leakage patterns or lesion size need to be characterized for treatment planning.
  • Indocyanine green angiography: Used selectively for deeper choroidal disease, including polypoidal choroidal vasculopathy.

The combination distinguishes wet AMD from look-alike conditions such as central serous retinopathy, polypoidal choroidal vasculopathy, and diabetic macular edema, and it tells us whether the disease is active and needs treatment now.

Anti-VEGF Therapy and the Modern Treatment Plan

Intravitreal anti-VEGF therapy is the established first-line treatment for wet AMD and has dramatically changed outcomes since the mid-2000s. The injection itself takes seconds. The eye is numbed with topical anesthetic, a small amount of medication is injected through the white of the eye into the vitreous cavity, and the entry site self-seals. Standard guidance recommends an initial loading phase of three monthly injections, followed by an individualized maintenance schedule informed by OCT findings.

Treat-and-Extend, Not Endless Monthly Injections

The historical fear with wet AMD has been a lifetime of monthly office visits. That picture has changed. The dominant strategy today is treat-and-extend: after a loading phase, the interval between injections is lengthened in two-week increments as long as the OCT shows a dry, stable retina, and shortened only when fluid returns. Real-world registry data from US retina practices show that a substantial proportion of patients reach intervals of 12 weeks or longer within the first two years.

Two specific therapeutic advances drive that durability. First, the phase 3 TENAYA and LUCERNE trials of faricimab, a bispecific antibody targeting both VEGF-A and angiopoietin-2, showed visual gains noninferior to standard aflibercept while allowing dosing intervals up to every 16 weeks. Two-year follow-up confirmed durability: at week 112, roughly 60 to 67 percent of faricimab patients across the two trials were on every-16-week dosing, and 74 to 81 percent were on every-12-week or longer dosing.

Second, high-dose aflibercept 8 mg, evaluated in the phase 3 PULSAR trial, achieved noninferior vision gains versus standard aflibercept 2 mg at 12-week or 16-week dosing intervals after the loading phase, with the majority of patients maintaining those extended intervals through 48 and 96 weeks.

Comparing Modern Anti-VEGF Agents

There is no universally “best” anti-VEGF drug for wet AMD. There is a best fit for a given eye, disease pattern, prior treatment response, and insurance situation. The agents we use most often in New York City practice include:

  • Aflibercept 2 mg (EYLEA) and aflibercept 8 mg (EYLEA HD): VEGF trap proteins. The 8 mg formulation enables longer intervals than the 2 mg, with comparable safety in the PULSAR trial.
  • Faricimab (Vabysmo): The first bispecific antibody for the eye, targeting VEGF-A and Ang-2. Meta-analytic data show comparable visual outcomes to monospecific anti-VEGF agents, with similar ocular safety.
  • Ranibizumab (Lucentis) and biosimilars: The first widely used agent for wet AMD, still appropriate in many cases.
  • Bevacizumab (Avastin): Used off-label for wet AMD. Major NICE and other guideline reviews have found no clinically significant difference in efficacy or safety between bevacizumab, ranibizumab, and aflibercept for wet AMD, and it is substantially less expensive.
  • Brolucizumab (Beovu): A single-chain antibody fragment available for selected patients, with informed-consent discussion about rare intraocular inflammation.

A recent network meta-analysis of 49 randomized trials including more than 23,000 eyes concluded that faricimab 6 mg or aflibercept 8 mg, in a loading phase followed by a treat-and-extend or fixed extended regimen, offers the best balance of visual outcomes, anatomic control, and reduced treatment burden.

What the Injection Visit Looks Like

A typical wet AMD visit at NY LASIK takes about 60 to 90 minutes and includes a dilated exam, OCT imaging, and, when needed, the injection itself. The eye is numbed, the lids and ocular surface are cleansed with a povidone-iodine antiseptic to minimize infection risk, and the medication is injected with a fine needle. Endophthalmitis, the most serious risk, occurs at a rate of roughly 0.02 to 0.09 percent per injection in contemporary series, and large clinical trials have shown a 0.7 to 1.6 percent incidence across the full course of treatment. Mild floaters, brief blur, and minor surface irritation are common for a day or two; significant pain, light sensitivity, or vision drop after an injection is not normal and requires same-day evaluation.

happy senior woman commuting on the city bus

Who Benefits Most From Treatment

The strongest visual outcomes are seen in patients who begin treatment soon after symptoms appear, before macular scarring forms. Ideal candidates include:

  • Patients with newly diagnosed active wet AMD confirmed on OCT
  • Patients with previously treated wet AMD who have switched practices or want a second opinion on an extended-interval plan
  • Patients whose treatment burden has become unsustainable and who may be candidates for switching to a longer-acting agent
  • Patients with reactivation of previous dry disease

Wet AMD treatment is less likely to recover vision when the macula already has dense subretinal hemorrhage, established disciform scarring, or geographic atrophy involving the foveal center. In those cases, our focus shifts to preserving the remaining vision and connecting patients with low-vision rehabilitation. A small subset of patients with submacular hemorrhage may benefit from surgical intervention, evaluated case by case.

mature woman using reading glasses to read her book

Why Choose NY LASIK for Wet AMD Care

NY LASIK is led by Leonard Bley, MD, FACS, a board-certified ophthalmologist with more than 30 years of experience and over 100,000 procedures performed. Dr. Bley has been involved in refractive surgery since 1989, before LASIK received FDA approval. He holds the FACS designation and is EVO-Certified.

Dr. Bley founded NY LASIK as part of the Laser and Microsurgery Institute. The goal was an integrated practice where refractive surgery, cataract surgery, glaucoma management, and retinal disease are managed under one roof. For wet AMD specifically, our team works directly with Dr. Moshe M. Szlechter, our in-house retina surgeon, for injection management and long-term disease monitoring.

The same physician who diagnoses your wet AMD manages your injections and your ongoing plan. Many of our patients are referred by primary eye care providers across Manhattan, Brooklyn, Queens, and the greater New York metro area. Spanish-language support is available on request. For related conditions, see our pages on diabetic retinopathy and comprehensive retina services.

Frequently Asked Questions

No, not necessarily. Most patients with wet AMD start with three monthly loading injections, then shift to a treat-and-extend schedule that lengthens the interval as long as the OCT remains dry. Newer agents such as faricimab and aflibercept 8 mg allow many patients to space injections to every 12 to 16 weeks, and roughly 60 to 67 percent of faricimab-treated patients in TENAYA and LUCERNE reached every-16-week dosing by two years.

The injection itself is brief and most patients describe it as pressure rather than pain. The eye is numbed with topical anesthetic before the needle is introduced, and the entry site is so small it self-seals. Mild scratchiness, a small red spot on the white of the eye, or brief floaters are common for a day; significant pain or vision drop is not.

No. Dry AMD is the slow accumulation of drusen and gradual thinning of the retinal pigment epithelium, and roughly 85 to 90 percent of all AMD cases are dry. Wet AMD is defined by the growth of abnormal blood vessels under the retina that leak fluid or blood, and it can cause rapid, severe central vision loss if untreated. Patients with dry AMD can develop wet AMD, which is why central-vision self-monitoring matters.

Supplements do not treat active wet AMD. In the National Eye Institute’s AREDS and AREDS2 trials, daily high-dose antioxidant and zinc supplementation reduced the risk of progression from intermediate AMD to advanced AMD by approximately 25 percent, but the formula does not reverse neovascularization once it has begun. Patients with active wet AMD still need anti-VEGF injections.

OCT is performed at almost every visit, because the decision to extend or shorten the interval depends on whether fluid is present in the retina. OCT angiography, fluorescein angiography, or indocyanine green angiography are added when the picture is unclear, the disease is not responding as expected, or another diagnosis is being considered.

Wet AMD that is undertreated returns. Real-world studies have shown that patients with neovascular AMD are frequently undertreated and lose visual potential because of missed injections. If a visit is missed, vision changes can occur within weeks, which is why we coordinate with patients and family members to keep the schedule on track.

Source Index

  1. Fleckenstein M, Schmitz-Valckenberg S, Chakravarthy U. “Age-Related Macular Degeneration: A Review.” JAMA. 2024;331(2):147-157. https://doi.org/10.1001/jama.2023.26074
  2. Heier JS, Khanani AM, Quezada Ruiz C, et al; TENAYA and LUCERNE Investigators. “Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.” Lancet. 2022;399:729-740. https://doi.org/10.1016/S0140-6736(22)00010-1
  3. Agostini H, Abreu F, Baumal CR, et al. “Faricimab for neovascular age-related macular degeneration and diabetic macular edema: from preclinical studies to phase 3 outcomes.” Graefe’s Archive for Clinical and Experimental Ophthalmology. 2024;262(11):3437-3451. https://doi.org/10.1007/s00417-024-06531-9
  4. Nichani PAH, Popovic MM, Mihalache A, et al. “Efficacy and Safety of Intravitreal Faricimab in Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema, and Retinal Vein Occlusion: A Meta-Analysis.” Ophthalmologica. 2024;247(5-6):355-372. https://doi.org/10.1159/000541662
  5. Butler ETS, Arnold-Vangsted A, Schou MG, et al. “Comparative efficacy of intravitreal anti-VEGF therapy for neovascular age-related macular degeneration: A systematic review with network meta-analysis.” Acta Ophthalmologica. 2025;103(7):741-763. https://doi.org/10.1111/aos.17506
  6. Lanzetta P, Korobelnik JF, Heier JS, et al; PULSAR Investigators. “Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial.” Lancet. 2024;403(10432):1141-1152. https://doi.org/10.1016/S0140-6736(24)00063-1

The content on this page was authored and medically reviewed by Dr. Leonard M. Bley, MD, FACS, founder of NY LASIK and Surgical Director of Laser and Microsurgery Institute. Dr. Bley is an internationally recognized, board-certified refractive and cataract surgeon with over 35 years of clinical experience and more than 30,000 vision correction procedures performed across our Manhattan, Brooklyn, and Queens offices. A Fellow of the American Academy of Ophthalmology and member of the American College of Eye Surgeons, he trained at Manhattan Eye, Ear and Throat Hospital and completed fellowship training at New York University Hospital, with hospital affiliations at NYU Langone and Staten Island University Hospital. By combining decades of surgical expertise with a commitment to evidence-based, patient-centered care, our team ensures all content on this site reflects the most current and accurate information in refractive surgery, cataract care, and advanced eye health.